Patient with Down syndrome and relapsed acute lymphoblastic leukemia with sustained remission despite only partial R3 chemotherapy

DS‐ALL has a higher rate of relapse and treatment‐related mortality. The newer immunotherapies are potentially better options. Relapsed ALL with positive MRD has a poor prognosis. Transient long‐term remission after ALL relapse due to partial chemotherapy combined severe infection is rare.

Detalles Bibliográficos
Autores principales: Hu, Zhongbo, VanHeyst, Kristen A., Dalal, Jignesh, Hackney, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981660/
https://www.ncbi.nlm.nih.gov/pubmed/33768794
http://dx.doi.org/10.1002/ccr3.3678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981660/
https://www.ncbi.nlm.nih.gov/pubmed/33768794
http://dx.doi.org/10.1002/ccr3.3678

Ejemplares similares